CD43
- Known as:
- CD43
- Catalog number:
- 1P-220-T100
- Product Quantity:
- 100 tests
- Category:
- -
- Supplier:
- Exbio
- Gene target:
- CD43
Related genes to: CD43
- Gene:
- SPN NIH gene
- Name:
- sialophorin
- Previous symbol:
- -
- Synonyms:
- LSN, CD43, GPL115
- Chromosome:
- 16p11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1988-08-31
- Date modifiied:
- 2016-07-19
Related products to: CD43
Related articles to: CD43
- Surgical resection is the primary treatment for solid pseudopapillary neoplasms (SPN). Systemic treatment options are limited; no prospective trials or consensus guidelines exist given the rarity of SPN. - Source: PubMed
Publication date: 2026/10/07
Porfido CourtneyReidy-Lagunes DianeRaj Nitya - Powder segregation is a critical quality risk in solid dosage manufacturing, yet current risk assessment is resource-intensive hence poorly suited to early formulation screening. This work addresses that by introducing a mechanistic predictive framework linking constituent particle properties and blend flowability to segregation risk. Binary blends of two ibuprofen grades (IBU25, IBU70) and micronized acetaminophen (mAPAP) with eight pharmaceutical excipients (n = 24 total) were characterized for particle size, shape, density, and flow function coefficient (FFC). Segregation was quantified by NIR spectroscopy (SPECTester) using Segregation Intensity (SI) and Cumulative Segregation Area (CSA), a composition-integrated metric. Particle size-density disparity between API and excipient establishes the mechanical driving force for segregation, while blend flowability determines how fully that potential is expressed; neither factor alone is sufficient, but together they could be predictive. Consequently, a dimensionless Particle Mechanical Property Factor (PMPF), combining D, ratio and bulk density ratio, was introduced as a pre-formulation disparity descriptor, leading to a novel parameter called the Segregation Propensity Number (SPN) as the product PMPF × FFC. It was used in a power-law model y = k(SPN), trained on IBU25 and mAPAP blends (n = 16) and validated on held-out IBU70 blends (n = 8) achieved R_ext = 0.95 for CSA and R_ext = 0.84 for SI, with CSA showing superior generalizability and minimal systematic bias. This framework is expected to enable a priori segregation risk assessment from routinely collected particle data paired with a single blend flowability measurement, supporting QbD-driven excipient selection and early formulation development. - Source: PubMed
Publication date: 2026/10/06
Owasit AnnaTripathi SiddharthDavé Rajesh - Foot drop is a common post-stroke gait impairment that reduces toe clearance and compromises walking safety. Existing assistive interventions are often limited by passive compensation, external power requirements, and manual tuning. Here, we introduce a wearable, gait-timing-adaptive, self‑powered neuroprosthesis (SPN) that augments ankle dorsiflexion and corrects gait patterns, avoiding labor-intensive parameter tuning and eliminating the charging and reliability burdens of external batteries. The SPN leverages gait's out‑of‑phase mechanics: it harvests mechanical energy during stance on the non‑paretic limb and immediately converts it into electrical stimulation of the tibialis anterior on the paretic limb during swing, increasing dorsiflexion when foot clearance is required. In ambulatory stroke survivors with preserved walking capacity, foot drop, and lower-limb impairment (Fugl-Meyer LE Score: 13-27/34, Modified Ashworth Scale-Ankle Plantarflexors: 0-2), the SPN assistance produced immediate, clinically meaningful gains during outdoor walking: dorsiflexion angle improved from -1.1° to 6.8°, walking distance increased by 67.3%, speed by 43.5%, and gait variability decreased by 71.9%. These findings demonstrate the SPN's potential to restore dorsiflexion, enhance mobility, and improve overall quality of life for individuals recovering from stroke, particularly those at later stages of life. - Source: PubMed
Publication date: 2026/09/02
Pan QiqiLuo YuyanLong ZhiheLiang HaobingZheng YiWang YuanyiBai SongnanZhang JiawenPang MinLiang RiranLin WeikangDong FeipengLi ZixuanYang XiaodanWang BiaoHong YingHan BinMa Christina Zong-HaoYang Zhengbao - More than 200 monoclonal antibodies (mAbs) are approved for clinical use, yet their therapeutic potential is constrained by dependence on repeated injections or infusions that drive nonadherence, limit access in low-resource settings, and generate peak-trough pharmacokinetics linked to adverse effects and reduced efficacy. Here, we developed an immunomodulatory, encapsulated cell-based "biologics factory" that overcomes mAb instability, immunogenicity, and the fibrotic foreign body response that have limited previous approaches, enabling continuous in situ production of therapeutic antibodies from a single administration. Screening chemically modified alginate biomaterials in immunocompetent mice identified a lead immunomodulatory alginate formulation that sustains stable serum titers of the HIV-neutralizing mAb 3BNC117 for 1 year. Single-cell RNA sequencing revealed that this formulation promotes a local anti-inflammatory, proresolving immune niche that attenuates fibrosis. The platform's versatility was demonstrated by the production of 13 diverse mAbs from an allogeneic cell chassis, with sustained in vivo delivery of a subset including ipilimumab, pembrolizumab, adalimumab, and PGT121. Integration into a retrievable macrodevice enabled on-demand therapeutic termination and reimplantation for dose-proportional tuning. In a nonhuman primate, subcutaneous implantation maintained stable ipilimumab titers for more than 6 months with no detectable toxicity, antidrug antibodies, or adverse events, and dose-dependent exposure was confirmed across a three-dose escalation. These results demonstrate a clinically translatable platform that offers a practical strategy to replace frequent injections with single-administration therapy. A cell-based delivery platform within an antifibrotic minimally invasive device enables year-long mAb delivery. - Source: PubMed
Publication date: 2026/10/02
Fell CodyDavis Anthony EPandey ShaliniGuinn Michael TWang ZeshiDeBonis JonathonSmith ChancellorBrown NathanMurungi DannaKim YeonjuMohandessi ImaanBednarz PatrickArdeshir AmirHaupt Erin MCuevas Samuel ILavine Christy LSeaman Michael SIgoshin OlegGhanta Ravi KDiehl Michael RVeiseh Omid - Solid pseudopapillary neoplasm (SPN) of the pancreas occurs predominantly in young women and commonly contains hemorrhagic and degenerative components that can complicate imaging assessment. We report the case of a 19-year-old woman who presented with abdominal distension and decreased appetite. Multiphasic abdominal CT, including an unenhanced phase, demonstrated a well-circumscribed cystic and solid mass in the pancreatic head, with internally hyperattenuating areas on the unenhanced images and mild heterogeneous enhancement of the non-cystic component. MRI demonstrated peripheral and internal intrinsic T1 hyperintensity, compatible with blood products, markedly heterogeneous T2 signal, and restricted diffusion in a non-cystic portion that also showed post-contrast enhancement, along with an enhancing capsule. The measured apparent diffusion coefficient (ADC) was approximately 0.98 × 10⁻³ mm²/s. Because clotted blood may also restrict diffusion, the diffusion-weighted imaging (DWI) and ADC findings were interpreted together with the conventional and post-contrast images rather than being used alone to identify viable tumor tissue. The patient underwent laparoscopic pancreaticoduodenectomy. Gross examination revealed a cystic and solid tumor containing abundant bloody fluid, and microscopy confirmed conspicuous hemorrhage. Immunohistochemistry showed nuclear and cytoplasmic β-catenin positivity, nuclear progesterone receptor positivity, and CD10 and vimentin positivity, supporting the diagnosis of SPN. Resection margins and sampled lymph nodes were negative. Correlative analysis of CT and MRI findings with pathological and immunophenotypic features may improve diagnostic confidence. - Source: PubMed
Publication date: 2026/08/31
Ma HaoYin JiaxinZhang Xianglin